IDH2

Kerri FitzgeraldAcute Myeloid Leukemia | October 3, 2022

The efficacy of enasidenib in patients with AML depends on the mutation type.

Cecilia BrownMyelodysplastic Syndromes | September 13, 2022

It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome.

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University